Yen’s Rise, Slow New Drug Launches Cloud Astellas’ 2008 Earnings Outlook
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Having no large extra charges for acquisitions like its Japanese competitors, Astellas Pharma predicted Nov. 5 revenues and earnings for fiscal 2008 would be slightly better than its earlier forecast but the yen's appreciation and slow new drug launches would nudge the performance modestly lower than in the preceding business year